Sign in

You're signed outSign in or to get full access.

ST

Sionna Therapeutics, Inc. (SION)·Q1 2025 Earnings Summary

Executive Summary

  • Pre-revenue biotech quarter with disciplined R&D execution and a larger net loss driven by higher operating expenses post-IPO; cash and equivalents rose to $354.7M, extending runway into 2028, reducing near-term financing risk .
  • EPS missed S&P Global consensus: ($0.62) actual vs ($0.45) consensus; revenue in line with consensus at effectively $0 given no revenue line was reported in Q1 financials (3 estimates) . EPS consensus from S&P Global: ($0.45)*.
  • Operationally, Sionna completed Phase 1 dosing for NBD1 stabilizers SION-719 and SION-451 during the quarter and, shortly after, announced positive topline Phase 1 safety/PK results (June 4), keeping Phase 2a add-on and dual-combo trial initiations on track for 2H25 and topline data in mid-2026 .
  • Key near-term catalysts: 2H25 trial initiations (add-on POC for SION-719 and healthy volunteer dual-combo with SION-451), with mid-2026 data; a solid balance sheet is a supportive backdrop for execution .

What Went Well and What Went Wrong

What Went Well

  • Phase 1 execution and tolerance: “Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated,” with topline data planned in 1H25 and later confirmed positive on June 4 .
  • Balance sheet strength: “Strong cash position following completed upsized IPO… approximately $354.7 million… expected to fund operations into 2028,” improving strategic flexibility .
  • Clear clinical path: “On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026” .

What Went Wrong

  • EPS miss vs consensus: ($0.62) actual vs ($0.45) consensus; miss driven by higher operating expenses (G&A step-up as a new public company and program costs) . EPS consensus from S&P Global: ($0.45)*.
  • Operating expense growth: Total OpEx increased to $19.7M from $13.1M YoY (+49.6% YoY), with G&A nearly doubling YoY ($6.0M vs $2.9M) due to personnel and professional fees, and R&D up to $13.7M vs $10.2M .
  • Limited external read-through on efficacy: While Phase 1 safety/PK is encouraging, efficacy readouts rely on upcoming add-on and dual-combo studies; investors must wait for mid-2026 topline data to gauge clinical benefit .

Financial Results

P&L Summary (USD Thousands unless noted)

MetricQ1 2024Q4 2024Q1 2025
Research & Development$10,220 $14,254 $13,668
General & Administrative$2,927 $3,880 $5,991
Total Operating Expenses$13,147 $18,134 $19,659
Interest Income$1,132 $2,119 $3,000
Other Income$168 $167 $177
Net Loss$(11,847) $(15,848) $(16,482)
Net Loss per Share (basic & diluted)$(3.84) $(3.38) $(0.62)
Weighted Avg Shares (basic & diluted)3,082,635 4,691,141 26,596,059

Notes: Q1 2025 EPS decline vs consensus reflects higher OpEx; share count rose materially post-IPO, which reduced per-share loss despite a higher absolute net loss .

Balance Sheet Highlights

MetricDec 31, 2024Mar 31, 2025
Cash, Cash Equivalents & Marketable Securities$168,043 $354,688
Working Capital$140,573 $264,153
Total Assets$185,752 $369,674
Total Stockholders’ Equity (Deficit)$(163,713) $351,769

Results vs S&P Global Consensus (Q1 2025)

MetricActualConsensusSurprise
EPS (USD)$(0.62) $(0.45)*$(0.17)
Revenue (USD Millions)N/A (no revenue line reported) $0.0*N/A

Values with asterisks are retrieved from S&P Global.

KPIs (Clinical/Operational)

KPIQ4 2024 (context)Q1 2025Post-Q1 Update
Phase 1 dosing status (SION-719 / SION-451)MAD dosing completed for SION-451; final MAD cohort planned for SION-719 SAD/MAD, food effect, tablet BE completed for both in HV; well tolerated Positive topline Phase 1 data; both achieved PK targets
Subjects dosed——100 (SION-719), 110 (SION-451)
Cash runwayInto 2028 Into 2028 Reaffirmed

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Phase 1 topline (SION-719, SION-451)1H 2025Topline “in first half of 2025” “This quarter” (Q2 2025) Narrowed timing (more specific)
Phase 2a POC (SION-719 add-on to SOC)2H 2025 start; topline mid-2026Initiate 2H 2025; topline mid-2026 On track; initiate 2H 2025; topline mid-2026 Maintained
Dual combination MAD (SION-451 + SION-2222 and/or SION-109)2H 2025 start; topline mid-2026Initiate 2H 2025; topline mid-2026 On track; initiate 2H 2025; topline mid-2026 Maintained
Cash runwayMulti-year“Into 2028” “Into 2028” Maintained

Earnings Call Themes & Trends

Note: We did not find a Q1 2025 earnings call transcript in our document set. Management hosted a June 4 conference call related to Phase 1 results; the press release notes the call, but the transcript is not present in this corpus .

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q1 2025)Trend
R&D execution (NBD1 stabilizers)Q3’24: not available; Q4’24: MAD completed for SION-451; SION-719 final MAD planned; well tolerated Q1’25: SAD/MAD and Part C completed for both; well tolerated; topline in Q2 Improving execution; de-risked Phase 1
Clinical timelinesQ4’24: topline 1H25; 2H25 initiations; mid-2026 topline Q1’25: topline specified to “this quarter”; 2H25 initiations reaffirmed Timeline clarity improved
Cash runwayQ4’24: IPO completed; runway into 2028 Q1’25: $354.7M cash; into 2028 Strengthened/maintained
Regulatory——Post-Q1: FDA cleared IND for SION-719; DDI study initiated
Complementary modulators (SION-2222, SION-109)Q4’24: SION-109 Phase 1 completed; dual-combo plan outlined Q1’25: dual-combo path reaffirmed Stable plan

Management Commentary

  • “Following our upsized IPO in February, we are in a strong financial position to advance our mission to transform the treatment paradigm for patients with CF… We look forward to announcing topline data… and to initiating our Phase 2a POC trial and the combination MAD Phase 1 program later this year” — Mike Cloonan, President & CEO .
  • “Today’s announcement brings us one step closer to our vision of developing novel NBD1-led proprietary dual combinations… The successful completion of two NBD1 Phase 1 trials… are important milestones” — Mike Cloonan, following positive Phase 1 topline .
  • “Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic concentration targets… reinforcing the potential… either as an add-on to standard of care, or in a proprietary dual combination with complementary modulators” .

Q&A Highlights

  • We did not locate a Q1 2025 earnings call transcript; therefore, no Q&A highlights are available from an earnings call. Management did host a June 4 call to discuss Phase 1 topline results, but that transcript is not included in the documents accessed here .

Estimates Context

  • EPS missed S&P Global consensus: ($0.62) actual vs ($0.45) consensus; miss likely tied to higher G&A and continued R&D investment as outlined in the press release . EPS consensus from S&P Global: ($0.45)*.
  • Revenue in line with consensus at effectively zero; the company reported no revenue line in the Q1 statement of operations; consensus revenue was $0.0* .
  • Estimate revisions may edge modestly more conservative on near-term quarterly EPS given elevated G&A as a public company, though interest income tailwinds from a larger cash balance may partially offset .

Values with asterisks are retrieved from S&P Global.

Key Takeaways for Investors

  • The balance sheet is a differentiator: $354.7M in cash and equivalents and runway into 2028 provide funding for multiple clinical inflection points without near-term financing overhang .
  • Clinical momentum continues: Phase 1 completion and positive topline safety/PK materially de-risk the NBD1 stabilizer platform heading into 2H25 initiations (SION-719 add-on POC; SION-451 dual combo) .
  • Near-term setup: Program initiations in 2H25 represent the next set of catalysts; mid-2026 topline data across both paths will be the key efficacy readouts for CFTR normalization potential .
  • EPS variability likely persists while pre-revenue: Operating expenses are expected to remain the main driver; interest income on a larger cash base is a partial cushion .
  • Watch regulatory and operational execution: IND clearance for SION-719 and DDI work to enable add-on dosing are constructive signs of execution rigor .
  • Strategic narrative: Sionna is positioning for NBD1-led combinations designed to restore CFTR function toward normal—an outcome that, if demonstrated clinically, could be a significant value inflection .
  • Risk factors remain: As with all early clinical-stage biotechs, timelines and outcomes may vary; efficacy signals will be the core driver of value realization .

Values with asterisks are retrieved from S&P Global.